Photo of Iyad Sultan from researchgate.net
Jul 2, 2023, 07:46
LMICs struggle in the process of selecting potent drugs at suitable prices – Dr. Iyad Sultan
Italian hospitals have been treating children with cancer with Celginase, a drug unapproved in the EU but legal due to regulatory gaps. This drug, a form of L-asparaginase manufactured in Southern Asia, is one of the most important drugs in treating leukemia. It is a cheaper but substandard option for acute lymphoblastic leukemia, often used without patients’ knowledge. The situation highlights the urgent need for regulatory reform and greater transparency in drug import practices across EU. LMICs struggle in the process of selecting potent drugs at suitable prices, and such regulations may help Healthcare Scandal.
For details: Click here
Source: Dr. Iyad Sultan/Twitter
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 05:54
Dec 21, 2024, 05:42
Dec 21, 2024, 04:55
Dec 21, 2024, 03:42